Dosing and Administration for RECARBRIO™ (imipenem, cilastatin, and relebactam)
Learn about:
RECARBRIO™
(imipenem, cilastatin, and relebactam) for injection 1.25 g
Learn about:
HABP/VABP | |
---|---|
Dose (g) | 1.25 |
Frequency | Every 6 hours |
Infusion time | 30 minutes |
Duration of treatment | 4 to 14 days |
cUTI | |
---|---|
Dose (g) | 1.25 |
Frequency | Every 6 hours |
Infusion time | 30 minutes |
Duration of treatment | 4 to 14 days |
cIAI | |
---|---|
Dose (g) | 1.25 |
Frequency | Every 6 hours |
Infusion time | 30 minutes |
Duration of treatment | 4 to 14 days |
cIAI, complicated intra-abdominal infections; CLcr, creatinine clearance; cUTI, complicated urinary tract infections; HABP/VABP, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; Q6H, every 6 hours
The recommended duration of treatment is 4 days to 14 days. The severity and location of infection, as well as clinical response, should guide the duration of therapy.
Patients who have CLcr less than 90 mL/min require dosage reduction of RECARBRIO, as shown below. For patients with fluctuating renal function, CLcr should be monitored.
Patients with CLcr less than 15 mL/min should not receive RECARBRIO unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of RECARBRIO for patients undergoing peritoneal dialysis.
Dosing resources
Dosing and Billing Guide
Dosing information as well as preparation, compatibility, and billing of the product.
RECARBRIO is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens.
RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis, and Pseudomonas aeruginosa.
Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Before prescribing RECARBRIO, please read the accompanying Prescribing Information.